|
|
 |
|
Viewing report
|
|
|
|
Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Dec 2011, Pages: 107
Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report “Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global ACS therapeutics market. The report identifies the key trends shaping and driving the global MI therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global MI sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData has estimated that the global ACS therapeutics market was valued at $6,055.3m in 2005, before increasing at a CAGR of 5.8% to reach $8,038.5m in 2010. The market is expected to increase to $8,428.2m by 2018, at a slow compound annual growth rate (CAGR) of 0.6%. The slow growth in the forecast period can be attributed to the patent expiries of major marketed products such as Lipitor (atorvastatin), Plavix (clopidogrel), Angiomax (bivalirudin), Effient (prasugrel), Integrilin (eptifibatide) and Aggrastat (tirofiban). The patent expiry of these major marketed products will attract generic versions of these drugs to the market. However, the expected approval and launch of novel first-in-class therapies such as varespladib from Anthera Pharmaceuticals, darapladib from GSK, dalcetrapib from F. Hoffmann-La Roche Ltd. /Japan tobacco, Xarelto (rivaroxaban) from Bayer, cangrelor from The Medicines Company and elinogrel (PRT128) from Novartis AG/Portola Pharmaceuticals Inc. will offset the impact of these expiries. As these products have novel mechanisms of action compared to currently marketed products, their cost of treatment is high, and therefore the market penetration of these therapies will be initially slow. Therefore, the ACS therapeutics market is expected to witness slow growth with a lot of generics playing a major role in the forecasted period, which is similar to the present market scenario.
Scope
The report provides information on the key drivers and challenges of the ACS therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) ACS therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Factor Xa inhibitors, P2Y (12) receptor antagonists, platelet aggregation inhibitors, CETP inhibitors and ADP receptor antagonists.
- Analysis of the current and future competition in the global TBI ACSmarket. Key market players covered are GlaxoSmithKline, The Medicine Company, Sanofi, Bayer AG/ Johnson & Johnson (J&J), F. Hoffmann-La Roche, Anthera Pharmaceuticals, Portola Pharmaceuticals/Novartis AG and Eisai Co., Ltd.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ACS therapeutics market.
- Analysis of key recent licensing and partnership agreements in ACS therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ACS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global ACS therapeutics market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
